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How can advances in genomic sciences be integrated into public
health in the developing world to deal with infectious diseases?
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Abstract Scientific and technological advances derived
from the genomics revolution have a central role to play in
dealing with continuing infectious disease threats in the
developing world caused by emerging and re-emerging
pathogens. These techniques, coupled with increasing
knowledge of host-pathogen interactions, can assist in the
early identification and containment of outbreaks as well as
in the development of preventive vaccination and thera-
peutic interventions, including the urgent need for new
antibiotics. However, the effective application of genomics
technologies faces key barriers and challenges which occur
at three stages: from the research to the products, from the
products to individual patients, and, finally, from patients to
entire populations. There needs to be an emphasis on
research in areas of greatest need, in facilitating the trans-
lation of research into interventions and, finally, the effec-
tive delivery of such interventions to those in greatest need.
Ultimate success will depend on bringing together science,
society and policy to develop effective public health
implementation strategies to provide health security and
health equity for all peoples.
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Abbreviations
ANDI African network for drugs and diagnostics
innovation
EPI Expanded programme on immunization
ICH-GCP International conference on harmonization-
good clinical practice
MDR Multi drug resistant
MRSA Methicillin-resistant Staphylococcus aureus
NIH National Institutes of Health
WHO World Health Organization
XDR Extensively drug resistant
Introduction
Unprecedented advances have been made in the advanced
genomic sciences with regards to new knowledge and
powerful technologies which relate to infectious diseases.
However, a major challenge is to ensure that these advances
have an impact on public health improvement and policies,
especially in the developing world. The present article will
identify the major infectious disease threats, the relevant
technologies, the barriers and hurdles which need to be
overcome, and the policy responses which need to be
instituted to successfully meet the challenges.
Infectious disease threats
Developing countries continue to struggle with emerging
and re-emerging infectious diseases. Recent outbreaks of
cholera (in Zimbabwe), meningitis and Ebola (in Africa),
chikungunya (in Southeast Asia, India, Sri Lanka, Kenya),
foot-and-mouth diseases (in China) and dengue (in Bolivia,
Southeast Asia) underscores the continuing threat in many
parts of the world. Avian influenza remains a major public
health threat and, based on studies of the 1918 global flu
pandemic, it has been estimated that a recurrence of such a
pandemic will kill between 50 and 80 million people
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worldwide, 95% of them in the developing world (Murray
et al. 2006), at an estimated economic cost of $3 trillion. In
addition, the threat of new pathogens emerging was illus-
trated by the appearance of a new arenavirus in South
Africa in 2008 which killed four out of five people it
infected (Keeton 2008). In addition, there are continued
concerns with the possibility and risk of pathogens crossing
the animal to human transmission barrier (Normile 2009).
Antibiotic resistance constitutes another major public
health threat (Taubes 2008) and includes MDR- (multi-drug
resistant) and XDR-TB (extensively-resistant tuberculosis),
MRSA (methicillin-resistant Staphylococcus aureus), van-
comycin-resistant Enterococcus and MDR Salmonella typhi.
In addition, there are concerns with the recent appearance of
resistance to artemisinin-combined therapy for malaria on
the Thai-Cambodia border and emergence of resistance
among influenza viruses to the antiviral agent oseltamivir
(tamiflu). It has been estimated that by 2009, 98% of cir-
culating influenza A/H1N1 virus strains in North America
have become resistant to oseltamivir (Layne et al. 2009) and
there are worrying reports of resistance developing among
the much more virulent H5N1 strain of influenza. In a recent
analysis of emerging and re-emerging infectious disease
threats globally, Jones et al. (2008) showed that approxi-
mately 60% of these threats came from zoonoses or wildlife
origins (e.g. wild birds in the case of avian influenza, bats in
the case of Nipah virus, etc.), 20% were vector borne agents
and 20% were due to antibiotic-resistant bacteria. ‘‘Hot
spots’’ of emergence of these threats were almost exclu-
sively located in the developing world, i.e. in tropical Asia,
central America and tropical Africa. Importantly, and iron-
ically, resources for surveillance and investigation of these
threats are focused in areas where the next emerging path-
ogen is least likely to come from, i.e. in the developed world.
Another important threat exists in the context of the
current global financial crisis (Horton 2009) and the reality
that the health budget is often the first to be cut in devel-
oping countries in times of scarce resources. It is also likely
that overseas development aid, which is relied upon by
many low-income countries for a significant portion of
their health budgets, may also be reduced in the coming
years. This may further weaken many health care delivery
systems in low and middle-income countries which are
already in a weak and fragile state, thus affecting their
ability to effectively respond to infectious disease threats.
Technologies derived from genomics
The genomics and post-genomics era has been accompa-
nied by an impressive array of new and powerful technol-
ogies which have a direct impact on the diagnosis, control
and prevention of infectious diseases. An analysis of the top
ten biotechnologies for improving health in developing
countries identified diagnostics, vaccines and drug and
vaccine delivery as the top three technologies (Daar et al.
2002). In broader terms, the list of key technologies include
the following:
1. The rapid identification of pathogens—this is the
cornerstone of surveillance and detection of new or re-
emerging pathogens and relies on the rapid sequencing
of pathogen sequences followed by comprehensive,
comparative analysis with genomic sequences present
in openly accessible databases.
2. Rapid, cheap, easy to use, point of care diagnostics—
ideally, these tests should be able to detect multiple
pathogens and be usable in least developed settings.
Better tests for TB and malaria, for example, can have a
significant impact on the burden of disease in affected
areas (Mabey et al. 2004).
3. Better, more effective, easily deployable vaccines—
beyond the traditional vaccines used in the EPI
(Expanded Programme on Immunization) there is also
a need to better utilize existing vaccines (e.g. against
typhoid, pneumonia) and develop more effective
vaccines in the future (e.g. against TB, malaria, HIV/
AIDS).
4. Genomics in drug discovery—pathogen genome
sequences, combined with other approaches such as
access to chemical libraries and molecular-target high
throughput screening, are the starting points of many
drug discovery and vaccine development initiatives
directed at neglected diseases affecting developing
countries e.g. the African Network for Drugs and
Diagnostics Innovation (ANDI) and Aeras, which
aims to develop new, safe and effective vaccine
regimens to prevent tuberculosis in children, adoles-
cents and adults.
5. Applications to vector control—the recent availability
of complete genome sequences for some major disease
vectors (e.g. Aedes spp., Anopheles spp.) will see some
important future applications for the control of these
disease-transmitting mosquitoes, including strategies
to reduce or eliminate their competence as vectors of
disease (Povelones et al. 2009).
6. Monitoring resistance (viral, bacterial, protozoal)—
molecular markers for development of resistance to
anti-microbial agents, rapidly deployed together with
diagnostic tests, is critical for surveillance and appro-
priate therapeutic responses.
7. Translating new knowledge of host-pathogen interac-
tions into better interventions—there is an increasingly
important body of knowledge which links infections
with the immune and inflammatory responses, including
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the genetic susceptibility to infectious diseases.
Advances in this field have important implications for
the development of therapeutics and diagnostics in the
future. Pharmacogenomics and personalized medicine,
for example, promises to improve drug safety and
efficacy (McGuire et al. 2007; Katsanis et al. 2008). A
recent study by Nijnik and Hancock (2009) described
the antimicrobial and immunomodulatory activities of
host-defence peptides and their potential applications
for tackling antibiotic-resistant infections.
With regard to future technologies, it is also useful to
consider areas where technology development is needed
for dealing with infectious disease threats. A ‘‘window’’
into what might constitute these priority research areas can
be gleaned from the recently announced US NIH Challenge
Grants in Health and Science Research (NIH 2009) which
highlighted the following as some of the priority areas:
1. Development of biomedical technologies and systems,
including the provision of ‘‘immediate diagnostic
information for multiple conditions at the point-of-
care’’;
2. New computational and statistical methods for the
analysis of large data sets from next-generation
sequencing technologies;
3. Theranostics—the combined delivery of diagnostic
and therapeutic agents;
4. Develop diagnostics and drugs for multiple- and
extensively drug-resistant tuberculosis;
5. Develop drugs for neglected tropical diseases, with a
special emphasis on malaria;
6. Novel approaches to improve immunogenicity of
vaccines against small molecules.
It is also important to emphasize that genomics-derived
technologies alone are not sufficient to deal with infectious
disease threats. A Foresight Report from the United King-
dom has identified that, in addition to genomics and post-
genomic approaches for rapid characterization of pathogens,
it is also important to consider innovative IT (information
technology) applications to capture, analyse and model data
(e.g. the use of hand held devices); non invasive mass
screening of people, animals and plants; and chip-based
portable diagnostic devices (King et al. 2006).
Barriers and challenges
The effective application of the technologies mentioned
above faces some key barriers and challenges which occur
at three stages: from the research to the products, from the
products to individual patients, and, finally, from patients
to entire populations.
Barrier 1—The R&D barrier: from publications
to products
The central questions here is: ‘‘are we doing the right
science to get the appropriate knowledge and interventions
with regards to both the areas and the types of research?
It has been estimated that approximately $160 billion
was invested in global health research & development
globally, compared to $85 billion in 1998 and $30 billion
in 1986 (Burke and Matlin 2008). Despite this influx of
funds, gaps and imbalances continue to exist in the
research process. The existence of the ‘‘10/90 gap’’, for
example, is well known where only 10% of global health
research funding is spent on 90% of the global disease
burden. There also exists a well-known market failure in
producing drugs for neglected tropical diseases in the
developing world—of 1,556 new drugs developed between
1975–2004, only 21 (1.3%) were for these diseases (Chirac
and Torreele 2006). In terms of support for various
research areas, a recent report analyzing funding patterns
among more than 100 donors found that 80% of the
funding were allocated to HIV/AIDS, TB and malaria
(Moran et al. 2009). In another analysis of the types of
research funded by the major UK agencies, it was found
that an average of only 1% of funding was allocated to
health services research (Rothwell 2006) with the bulk of
the funding going to biomedical, clinical and epidemio-
logical research.
More tellingly, most of the funding for health research is
focused on the development of new technologies, rather
than making use of existing interventions—in one analysis,
97% of grants were for the development of these new
technologies which was estimated to be able to reduce
child mortality by 22% (Leroy et al. 2007). However, if,
instead, research were focused on making better use of
existing technologies, the reduction in mortality can be
much higher at 66%. In the future, a lot more attention
needs to be paid to this field of implementation research.
Barrier 2—the translation barrier: from products
to patients
In the context of this barrier the key question is ‘‘do we
have the most efficient processes to ensure that effective
products benefits the patients?’’ In spite of the large
amounts of resources going into global health R&D, the
number of new drugs in the pipeline is actually decreasing
as exemplified by the lower number of new antibiotics
coming on the market. Clinical trials, the cornerstone of
getting drugs and other interventions to patients, are facing
major problems with regards to high costs, difficulties in
recruitment of trial participants, more regulations and
concerns about transparency and accountability. These
HUGO J (2009) 3:5–9 7
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concerns include unethical behavior on the part of phar-
maceutical companies, publication bias, and the non-
reporting of adverse events or negative results. Impor-
tantly, the developing countries will be affected as it has
been estimated that nearly 20% of clinical trials globally
now take place in the developing world, up from in 9% in
2003 (Normile 2008). Most of the increases are occurring
in Russia, India, China and Brazil. The main reasons for
increasing interest in conducting trials in the developing
world relate to lower costs, accelerated recruitment and
perceived ease of overcoming ethical and regulatory bar-
riers. There is also some concern about the over-regulation
of clinical trials, specifically the requirements to adhere to
the ICH-GCP guidelines which places too much emphasis
on the process rather than on the benefits to the patients
(White 2006; Farrar 2007). These bureaucratic require-
ments also place clinical trials beyond the reach of most
developing country investigators and disempowers them
from truly participating in the research and sharing in the
benefits.
Inefficiencies have also been noted in the diagnostics
field and an important question in this regard is ‘‘what is
the human and economic costs of bad diagnostics?’’ Many
developing countries lack stringent evaluation of diagnos-
tic tests and, in the case of dengue diagnostics, for exam-
ple, the claims of manufacturers were found to be well
short of acceptable standards (Blacksell et al. 2006). In a
more comprehensive analysis of diagnostic evaluations
reported in journals from 1978–1993, it was found that less
than half of the studies fulfilled more than three of the
seven methodological standards for diagnostics (Peeling
et al. 2006).
Barrier 3—the implementation barrier: from patients
to people
In some ways this is the most challenging of the three
barriers and focuses on the question ‘‘do we have the needed
delivery systems to get interventions to those in greatest
need?’’ Health systems failures and lack of access to the
most basic interventions are at the heart of the problem. For
example, Jones et al. (2003) found that less than 50% of
children in the developing world were receiving basic,
proven, effective and cheap interventions such as vitamin
A, tetanus immunization and insecticide-treated bednets.
Tragically, the gap in coverage for four interventions
(family planning, maternal and neonatal care, immuniza-
tion, and treatment of sick children) was larger for the
poorer segments of the population living in these countries
(WHO 2008). There are many reasons for these failures of
delivery but foremost among them are the shortage of health
workers, lack of reliable health information, insufficient
financing and poor infrastructure. In relation to health
workers, for example, Africa, which bears 25% of the
global burden of disease only has 2–3% of the global health
work force (WHO 2006). In addition, in many low-income
countries the recent deluge of external aid delivered through
multiple global health initiatives has created additional
problems and strains on already weak and fragile health
systems. There is evidence of fragmentation and lack of
coordination between these initiatives and they tend to be
‘‘top down’’ and donor-driven, with a focus on short-term
results around ‘‘big’’ diseases, thus creating vertical ‘‘silos’’,
rather than overall health system strengthening. In Haiti, for
example, a focus on HIV/AIDS testing and treatment
resulted in the neglect of testing for syphilis with the result
that children born to HIV-positive mothers were avoiding
HIV/AIDS but dying of syphilis (Peeling et al. 2004). With
many of these initiatives there is also a lack of evaluation of
the impact of their activities and limited accountability
mechanisms, thus bringing into question the longer term
sustainability of the activities.
In the context of this third barrier, another important
challenge is the weak linkages which exist between research
and policy development. Policy makers and researchers
have conflicting interests and often do not trust each other
(WHO 2004). Importantly, researchers need to present
science in a way which is understandable to policy makers
and able to answer the three questions they are most con-
cerned with: ‘‘can it work, will it work, is it worth it?’’ As
stated previously in a quote attributed to Sir Michael Mar-
mot, the reality is that ‘‘scientific findings do not fall on
blank minds that get made up as a result. Science engages
with busy minds that have strong views about how things
are and ought to be’’ and it is therefore important that
researchers and policy makers work together, perhaps
through ‘‘knowledge brokerage’’ mechanisms to more
effectively use scientific evidence in health policy devel-
opment. In the context of application of technological
advances derived from genomics this is particularly
important as the science is often complex and the benefits
not immediately obvious to the policy- and decision-
makers.
Conclusions
Genomics has made great strides in the past decade and its
importance for the diagnosis, treatment, prevention and
control of infectious diseases remains paramount. However,
and in order to have an impact on global public health, the
unprecedented scientific advances must be complemented
with efforts to apply resulting knowledge and technologies
to mitigate threats to health in the developing world. Bar-
riers between research and public health application must
be addressed and the mantra of ‘‘sequencing, sequencing,
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sequencing’’ should be counterbalanced by a call for
‘‘analysis, analysis, analysis’’, to which one can arguably
add a plea for ‘‘application, application, application’’.
Effective application, in turn depends on putting in place
the appropriate policy responses which should include
better alignment, harmonization and coordination of
genomics research so it addresses neglected areas. This
should be accompanied by the development of appropriate
capacity in developing countries through equitable part-
nerships, open and rapid sharing of information, develop-
ing inter-sectoral links and the facilitation of translation of
research to benefit patients. Finally, we need to develop a
more holistic, systems perspective to strengthen health
systems through better links of research to policy to
achieve scale up, impact and, ultimately, better health
outcomes and equity.
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